Company: CERO
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001213900-25-032134
Chunk: 2113

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 2
Chunk 2113
---
), which requires entities to provide more detailed disaggregation
of expenses in the income statement, focusing on the nature of the expenses rather than their function. The new disclosures will require
entities to separately present expenses for significant line items, including but not limited to, depreciation, amortization, and employee
compensation. Entities will also be required to provide a qualitative description of the amounts remaining in relevant expense captions
that are not separately disaggregated quantitatively, disclose the total amount of selling expenses and, in annual reporting periods,
provide a definition of what constitutes selling expenses. This pronouncement is effective for fiscal years beginning after December 15,
2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The Company is currently
assessing this ASU to determine the impact on its consolidated financial statements.

Management does not believe
that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the Company’s
consolidated financial statements.

F-12

NOTE 3 –
BUSINESS COMBINATION

Business Combination Agreement -
On June 6, 2023, CERo Therapeutics, Inc. (“Predecessor”), which was incorporated in Delaware on September 23, 2016, and based
in South San Francisco, California, entered into a Business Combination Agreement and Plan of Reorganization (the “BCA”)
with PBCE Merger Sub, Inc., a wholly-owned subsidiary of PBAX, and PBAX, with the surviving operating entity being named CERo Therapeutics
Holdings, Inc. (“Successor” or the “Company”), and such transaction, the “Business Combination” or
“Merger”.

The Company is focused on
genetically engineering human immune cells to fight cancer. The Predecessor focused on developing the CERo therapeutic platform and had
not yet begun clinical development or product commercialization. The Company’s efforts will focus on continued product development,
including clinical development, to support regulatory approval to commercialize and subsequent product commercialization.

The BCA was amended on February
5, 2024 and again on February 13, 2024. The Merger closed on February 14, 2024 (the “Closing”), at which time the following
occurred:

1.The outstanding shares of Predecessor’s Preferred Stock were converted into 44,155 shares of Common
Stock, par value $0.0001 per share (